ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
경카테터 승모판 수복 기기 시장 규모는 2023년 11억 9,706만 달러에서 예측 기간 동안 14.95%의 CAGR로 성장하여 2030년에는 27억 5,671만 달러 규모로 성장할 것으로 예상됩니다.
경카테터 승모판 수복 기기 시장은 순환기 질환, 다양한 심장판막 질환을 포함한 심혈관질환의 유병률 증가, 규제 허가 등 제품 개발 활동 증가, 좌식 생활습관과 관련된 장애 증가, 최소침습적 수술 선호 경향의 확대 등으로 인해 빠르게 성장하고 있습니다.
경카테터 승모판 수복 기기 : 시장 역학
British Heart Foundation(BHF)에 따르면, 라이프스타일의 변화와 고령화 등으로 인해 2022년에는 전 세계적으로 약 6억 4,000만 명이 심장 및 순환기 질환을 앓고 있는 것으로 보고되고 있습니다.
또한 WHO의 2020년 자료에 따르면, 석회 침착성 대동맥판막 협착증의 유병률은 전 세계적으로 900만 명으로 추산됩니다. 순환기 질환 및 다양한 심장판막 질환을 포함한 심혈관질환의 유병률 증가는 경카테터 승모판 수복 기기에 대한 수요를 증가시킬 것으로 예상됩니다.
최소침습적 수술에 대한 환자들의 선호도가 높아지는 것도 예측 기간 동안 시장 성장에 긍정적인 영향을 미칠 것으로 보입니다. 경카테터 승모판 수복 기기는 회복 시간 단축, 수술 후 통증 감소, 입원 기간 단축, 상처 합병증 감소, 더 나은 상처 보철물 등 최소침습적 접근 방식을 통해 기존 수술에 비해 이점을 제공합니다.
유형별로는 2023년 바이오 밸브 부문이 가장 큰 매출 점유율을 차지했습니다. 이는 재료 과학의 발전, 내구성 향상, 임상 적용 확대에 기인합니다.
돼지나 소의 조직에서 추출한 생체 판막은 우수한 혈역학적 성능, 혈전 유발성 감소, 평생 항응고 요법이 필요하지 않기 때문에 점점 더 선호되고 있으며, 특히 노약자나 활동적인 환자에게 유리합니다.
세계 경카테터 승모판 수복 기기 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 환경, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 경카테터 승모판 수복 기기 시장 보고서 : 소개
조사 범위
시장 분류
시장 상정
제2장 경카테터 승모판 수복 기기 시장 : 주요 요약
시장 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 경카테터 승모판 수복 기기 시장 : 주요 요인 분석
시장 성장 촉진요인
심혈관질환 이환율 증가
제품 개발 활동 강화
좌식생활습관 증가와 생활습관병 이환율 증가
시장 성장 억제요인과 과제
경카테터 승모판 수복술에 따른 리스크와 합병증
엄격한 규제 승인 프로세스
시장 기회
다수의 수복 기기가 파이프라인 중
제6장 경카테터 승모판 수복 기기 시장 : Porter's Five Forces 분석
제7장 경카테터 승모판 수복 기기 시장 평가
유형별
기계 판막
생체 판막
적응증별
승모판 역류증
승모판 협착증
기타
최종사용자별
병원
외래 수술 센터
지역별
북미
유럽
아시아태평양
기타 지역
제8장 경카테터 승모판 수복 기기 시장 : 기업·제품 프로파일
Abbott
Edwards Lifesciences Corporation
Shockwave Medical, Inc.
LivaNova PLC
NeoChord, Inc.
Coramaze Technologies
CryoLife, Inc.
JenaValve Technology, Inc.
Medtronic
Boston Scientific Corporation
제9장 KOL의 견해
제10장 프로젝트 접근법
제11장 DelveInsight 소개
제12장 면책사항·문의
ksm
영문 목차
영문목차
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and the increasing product developmental activities worldwide
The transcatheter mitral valve repair devices market was valued at USD 1,197.06 million in 2023, growing at a CAGR of 14.95% during the forecast period from 2024 to 2030 to reach USD 2,756.71 million by 2030. The transcatheter mitral valve repair devices market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases worldwide owing to changing lifestyles, aging, and a growing population.
As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter mitral valve repair devices.
The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter mitral valve repair devices offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.
Additionally, in January 2021, Cardiovascular Systems, Inc. received CE Mark for Diamondback 360(R) Coronary Orbital Atherectomy System.
Therefore, the factors stated above collectively will drive the overall transcatheter mitral valve repair devices market growth.
However, risk and complications associated with transcatheter mitral valve repair procedures, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter mitral valve repair devices market growth.
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the transcatheter mitral valve repair devices market, the bioprosthetic tissue (biological) valve category is expected to have a significant revenue share in the year 2023. This is due to the advancements in material science, enhanced durability, and expanding clinical applications.
Bioprosthetic valves, derived from porcine or bovine tissue, are increasingly preferred for their superior hemodynamic performance, reduced thrombogenicity, and elimination of lifelong anticoagulation therapy, which is particularly advantageous for elderly and active patients.
Further, the increasing product launches & approvals and other strategic activities will in turn propel the demand for bioprosthetic tissue valve devices. For instance, in September 2021, Abbott received US FDA approval for Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people suffering from aortic or mitral valve disease. Epic Plus, a bioprosthetic valve, do not require long-term use of blood-thinner medication, making them the recommended option for people, especially aged over 70 years who are at risk of taking blood thinners.
Therefore the widespread uses and various features of bioprosthetic tissue (biological) valve) enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall transcatheter mitral valve repair devices market:
Among all the regions, North America is expected to dominate the transcatheter mitral valve repair devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter mitral valve repair devices market in the North America region during the forecast period from 2024 to 2030.
Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.
According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.
Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter mitral valve repair devices.
Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter mitral valve repair devices. For example, in September 2022, Edwards Lifesciences received FDA approval for its Pascal Precision system. The device used minimally invasive surgery to repair the mitral valve in patients with degenerative mitral regurgitation, a condition where the valve between heart chambers does not close completely, allowing blood to leak back through.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter mitral valve repair devices market.
Some of the key market players operating in the transcatheter mitral valve repair devices market include Abbott, Edwards Lifesciences Corporation, Shockwave Medical, Inc., LivaNova PLC, NeoChord, Inc., Coramaze Technologies, CryoLife, Inc., JenaValve Technology, Inc., Medtronic, Boston Scientific Corporation, and others.
Recent Developmental Activities in the Transcatheter Mitral Valve Repair Devices Market:
In May 2024, 4C Medical Technologies, a Minnesota-based medical device company focused on structural heart disease, received the FDA's breakthrough device designation for its AltaValve System for transcatheter mitral valve replacement (TMVR).
In January 2023, Shockwave Medical, Inc., acquired Neovasc Inc., a company focused on the minimally invasive treatment of refractory angina, which is a chronic condition wherein a patient suffers chest pain that cannot be controlled by conventional therapies.
Key Takeaways from the Transcatheter Mitral Valve Repair Devices Market Report Study
Market size analysis for current transcatheter mitral valve repair devices market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the transcatheter mitral valve repair devices market
Various opportunities available for the other competitors in the transcatheter mitral valve repair devices market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current transcatheter mitral valve repair devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for transcatheter mitral valve repair devices market growth in the coming future?
Target Audience who can be benefited from this Transcatheter Mitral Valve Repair Devices Market Report Study
Transcatheter mitral valve repair devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in transcatheter mitral valve repair devices
Various end-users who want to know more about the transcatheter mitral valve repair devices market and the latest technological developments in the transcatheter mitral valve repair devices market
Frequently Asked Questions for the Transcatheter Mitral Valve Repair Devices Market:
1. What are transcatheter mitral valve repair devices?
The transcatheter mitral valve repair devices are cardiac surgical devices used to treat heart valve diseases such as regurgitation, stenosis, and prolapse. Transcatheter mitral valve treatment is a minimally invasive procedure to replace a mitral valve that is not working properly.
2. What is the market for transcatheter mitral valve repair devices?
The transcatheter mitral valve repair devices market was valued at USD 1,197.06 million in 2023, growing at a CAGR of 14.95% during the forecast period from 2024 to 2030 to reach USD 2,756.71 million by 2030.
3. What are the drivers for the Transcatheter Mitral Valve Repair Devices market?
The transcatheter mitral valve repair devices market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
4. Who are the key players operating in the transcatheter mitral valve repair devices market?
Some of the key market players operating in transcatheter mitral valve repair devices include Abbott, Edwards Lifesciences Corporation, Shockwave Medical, Inc., LivaNova PLC, NeoChord, Inc., Coramaze Technologies, CryoLife, Inc., JenaValve Technology, Inc., Medtronic, Boston Scientific Corporation, and others.
5. Which region has the highest share in the transcatheter mitral valve repair devices market?
Among all the regions, North America is expected to dominate the transcatheter mitral valve repair devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter mitral valve repair devices market in the North America region during the forecast period from 2024 to 2030.
